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Summary Little information is currently available on the use of hospital resources and the resulting costs of
treating any advanced cancer. Such data may be useful for planning purposes and for calculating the cost
effectiveness of measures designed to reduce the incidence of advanced disease (such as the National Breast
Screening Programme). A retrospective analysis of the medical records of 50 patients with advanced breast
cancer who attended the Guy's Hospital Oncology Unit and who died between October 1988 and December
1990 has therefore been undertaken. For each patient, the duration of in-patient stays and principal
indications for admissions were recorded, together with the number of out-patient attendances. Details of
endocrine treatment, chemotherapy and radiotherapy were abstracted as were all radiological and laboratory
investigations. Costs for each of these activities were calculated.
The median duration of advanced disease was 17 months (mean 27 months; range 7 days- 12 years). The
mean cost of treatment per patients was calculated to be £7,620 (range £317-£27,860). Mean duration of
in-patient stay was 32 days (0- 133) and this accounted for 56% of total costs. The large majority (>80%) of
the time spent as an in-patient was for the care of serious illness rather than for specific antitumour treatment.
Cytotoxic drugs accounted for 9% of the total cost, compared with 8% for radiotherapy and 13% for
laboratory and radiological investigations.
Following the implementation of the National Health Service
Act in April 1991, commissioning authorities have had to
negotiate contracts for services with providers of health. A
major problem in establishing such contracts is the lack of
information within the NHS regarding the use of resources
and their costs. Although it should be relatively straight-
forward to calculate the average cost of a single operation, it
is more complicated to establish the total cost of manage-
ment of a patient with a chronic disease, for example,
advanced cancer. However, unless direct billing for each item
of service is undertaken, it is essential that accurate calcula-
tions of average costs should be made in order to establish
appropriate contracts.
In parallel with this, methods for assessing the quality and
benefits of care received by patients are clearly required. Only
when such measures are available will it be possible to com-
pare patient management between different centres, and to
decide on appropriate allocation of finite resources. Within
an individual unit, however, an analysis of the costs of
managing a particular disease may given valuable insights
into how best to use scarce resources. In addition, the cost
effectiveness of measures designed to reduce the incidence of
advanced cancer (such as the National Breast Screening Pro-
gramme or the use of adjuvant systemic therapy) can only be
calculated if the cost of treating patients with advanced
disease is accurately known.
Patients who present with locally advanced or metastatic
breast cancer and those who develop metastases at some time
after their initial treatment are most likely to die from the
disease. The interval between first relapse and death varies
widely, ranging from only a few days to many years. Median
survival after the diagnosis of relapse is approximately 2
years, but it is impossible to predict prognosis for individual
patients accurately.
In this study the separate elements of care received by 50
patients with advanced breast cancer who were managed in a
specialised oncology unit at Guy's Hospital have been
analysed. The costs of each element of care have been
estimated and from this the total cost of management for
each patient has been calculated.
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Patients and methods
Patients
A computer database containing information on all patients
with breast cancer who have attended the Clinical Oncology
Unit at Guy's Hospital was used to identify patients who
were known to have died during the last 3 months of 1988
(n = 25) or at any time during 1990 (n = 88). The medical
records ofall 25 patients who had died in the first period and
a random selection of records of 50 patients from the second
period were examined for information regarding management
of advanced breast cancer. Twenty-five patients were ex-
cluded from further analysis, 13 of whom died of other
causes without ever having evidence of relapse of breast
cancer. Four patients received treatment for primary breast
cancer at Guy's, but treatment for advanced disease was
given exclusively at other hospitals. In the remaining eight
cases, care for advanced disease was shared electively with
other hospitals, as the patients lived outside the local health
district. Accurate information on resource usage was not
available for these patients. Hence, 50 patients whose man-
agement for advanced cancer was undertaken principally at
Guy's Hospital form the basis of this study. These included
patients who were managed in conjunction with a hospice or
home care support team and patients who presented as
emergencies to other hospitals and were then referred to
Guy's for subsequent management.
Detailed information was retrieved from the case records
ofeach of the 50 patients in the study for the period between
the development of advanced disease and death. For patients
who had initially presented with operable disease, the date of
diagnosis of distant metastasis or inoperable locoregional
recurrence was taken as the onset of advanced disease.
Contralateral breast tumours and operable recurrences within
a conserved breast diagnosed before this time were not con-
sidered as advanced disease. For patients who presented with
inoperable locally advanced disease and for those with overt
metastases at the time of diagnosis, the date of presentation
to the unit was taken as the date of advanced disease.
The following information was recorded for each patient:
Duration ofin-patient admissions, together with the principal
indication for each admission; Number of out-patient visits
to surgical, radiotherapy and medical oncology clinics; All
surgical, radiotherapy, endocrine and chemotherapy treat-
ments administered; All laboratory and radiological inves-
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tigations; Participation in research studies; Place of death;
Cause of death and whether a hospice or home care team
was involved in the patient's management. Emergency man-
agement in other hospitals was noted, but excluded from the
analysis of total costs.
Costing methodology
In-patient costs
Patients were managed on a ward designated for patients
with breast diseases (The Hedley Atkins Unit). The cost of
an overnight stay was estimated by calculating the total cost
of running the ward and dividing this by the total number of
overnight stays for the year 1988/89. No account was taken
of the complexity of care on the ward for an individual
patient. In a small minority of cases (5% - see Results)
patients were managed on other specialist wards (orthopaedic
or neurosurgical). For simplicity, in-patient costs have been
taken to be the same as those for the oncology ward. Salaries
including employers National Insurance Contribution and
London weighting for staff employed on the ward (e.g.
nurses) were calculated at a March 1991 pay and price base.
The proportion of the working week attributable to the
management of Breast Unit in-patients was calculated for
other staff (e.g. doctors, physiotherapists, dieticians) and
costs were calculated accordingly. This included staff em-
ployed by the University of London or funded by the
Imperial Cancer Research Fund. In addition, both direct
(e.g. portering and domestic services) and indirect overheads
(e.g. hospital administration) were included in the calculation
of costs. A further 19% was added to the calculated cost to
cover the capital charges applicable to the Guy's and
Lewisham NHS Trust in the year 1991-92.
Medical andsurgical out-patient costs
Each member of staff involved in out-patient clinics was
asked to identify the amount of time devoted to that clinic,
including time spent on supporting administration. A total
cost for each clinic including consumables (other than
cytotoxic drugs), direct and indirect overheads and capital
charges was calculated and divided by the average number of
patients attending that clinic to give a cost per patient.
Separate costs were established for medical clinics relating to
endocrine treatment and those in which chemotherapy was
administered.
Radiotherapy costs
Radiotherapy treatment and out-patient clinic visits are
under the management of the South East London Radio-
therapy Centre (covering Guy's, St Thomas' and King's Col-
lege Hospitals), whereas in-patient costs for radiotherapy at
Guy's Hospital fall within the budget of the Oncology Dir-
ectorate. In this study, radiotherapy treatment and out-
patient clinics were not costed separately. The cost of an
out-patient visit was arbitrarily taken to be the same as a
visit to the medical endocrine treatment clinic. The cost of a
fraction of radiotherapy (£37) used in the current analysis
was based on the findings of Goddard and coworkers in a
recent study of the cost of palliative radiotherapy at Mount
Vernon Hospital, Northwood, Middlesex (Goddard et al.,
1991). This figure is in line with the £30 cost calculated in
1988 by Goddard and Hutton based on the reports of
Greene (1983) and Atherton (1984).
Chemotherapy
The number of cycles of each chemotherapeutic regimen
administered and the duration in months of each endocrine
treatment was established for each patient. Current (1991)
costs of drugs at Guy's Hospital were used for the calcula-
tion of total costs of chemotherapy and endocrine therapy.
Surgery
The average length of each type of operation performed over
a 6 month period was determined by using the Theatre
Financial Information Project (FIP) system which records the
details of each operation performed in the Guy's Theatres.
The average length of each operation multiplied by the staff
cost per hour gives the staff cost per operation. To this were
added the costs of anaesthetic consumables and surgical and
medical equipment used together with a proportion of the
direct and indirect overheads for running the operating
theatre. Capital charges (19%) were added to this cost.
Radiology and laboratory investigations
All investigations undertaken on each patient were recorded.
Costings for each item were kindly provided by the
Pathology and Radiology Directorates in order to calculate
the total cost ofinvestigations for each patient. These include
the cost of consumables, staff and direct overheads.
Sensitivity analysis
Cost estimates are subject to error. The impact ofchanges on
the costs of individual items was therefore assessed by
performing a sensitivity analysis. The sensitivity to variations
in costs was defined as the percentage change that would be
required to increase overall cost by 1%.
Results
Thirty-one of the patients had initially presented with
operable breast cancer, 12 presented with locally advanced
disease and seven had overt metastases at the time of first
diagnosis. Nine patients lived in the health district served by
Guy's, 33 in other districts within the South East Thames
Region and eight in other health regions. Mean age at first
diagnosis was 58 years (range 32 to 85) and at the onset of
advanced disease was 60.5 years (range 32 to 87). Median
duration ofadvanced disease was 17 months (range 7 days to
12 years). Twenty-three of the patients died at Guy's, 14 at
home and 13 in a hospice.
In-patient stays
The 50 patients spent a total of 1,677 nights in hospital,
1,588 of which (95%) were spent on the designated oncology
ward. The mean number of overnight stays in hospital was
34 (range 0-133: Table I). In most (>80%) cases it was
possible to identify a principal indication for each admission
from the in-patient records and discharge summary. Bone
metastases causing pain, immobility, pathological fractures,
hypercalcaemia or spinal cord compression accounted for
36% of all overnight stays. In many cases patients received
Table I In-patient stays
No. of Nights in hospital
Indication patients Total %
Assessment/staginga 24 134 8
Chemotherapy/neutropenia 19 76 5
Bone/spinal cord compressionb 12 602 36
Lung/pleural/pericardial 11 239 14
complications
Liver metastases 6 45 3
Brain metastases 6 220 13
Metastases at multiple sites 22 274 16
Other surgeryc 6 65 4
Research 4 42 3
Total 1677
aIncludes diagnostic surgical procedures (e.g. excision biopsy of a
lymph node). bIncludes orthopaedic surgery. ce.g. palliative mastec-
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palliative radiotherapy during these admissions, but were not
sufficiently mobile to attend the radiotherapy department as
out-patients. In particular, eight patients spent a total of 561
nights (range 25-120) in hospital because of spinal cord
compression or pathological fractures.
Illness related to cerebral, liver, pulmonary, pleural or
pericardial metastases or a combination of these sites of
disease accounted for 46% of time spent as in-patients. In
some instances patients received chemotherapy during the
course of an admission, but the treatment did not add to the
duration of stay.
Twenty-seven of the 50 patients received cytotoxic
chemotherapy for advanced disease. In general this was given
as an out-patient except for the first cycle when overnight
admission was recommended for acute side effects to be
observed. Administration of chemotherapy and admissions
resulting from chemotherapy-induced myelosuppression ac-
counted for 76 of the 1,677 (5%) nights in hospital.
All patients who had participated in clinical research trials
were identified. When this was the reason for an admission,
or when an admission was prolonged for research purposes
(e.g. to collect blood samples for pharmacokinetic studies),
the extra time in hospital was calculated. A total of 42 nights
in hospital were attributable to research, 37 of these in one
patient who received two experimental drug treatments.
Specific treatment
Twelve patients underwent some form of palliative surgery
(e.g. palliative mastectomy, talc pleurodesis or orthopaedic
procedures) during the course of their illness. Thirty-three
patients received a total of 75 courses of radiotherapy (765
fractions). Forty-five received some form of systemic therapy
(18 endocrine treatment only; five chemotherapy only and 22
both chemotherapy and endocrine therapy). The mean dura-
tion of endocrine therapy for the 38 patients treated was 16
months (range 1 to 96). The 27 patients treated with
cytotoxic agents received a total of 225 cycles (range 1-43).
The total number ofclinic visits were as follows: surgical 170;
radiotherapy 354; endocrine 624 and chemotherapy 301.
Investigations
Details of the number of different radiological and
laboratory investigations undertaken on the 50 patients are
shown in Table II and III. Radionuclide bone scans
accounted for 41% of the total cost of radiological investiga-
Table II Radiological investigations
Total Mean per % oftotal cost
Investigations number patient ofradiology
Bone radiograph 420 8.4 20
Chest radiograph 299 6.0 10
Radionuclide bone scan 144 2.9 41
Radionuclide liver scan 34 0.7 8
Ultrasound 30 0.6 3
CT scan 16 0.3 7
Gated cardiac scan 7 0.1 3
Othera - - 8
Total 100%
aIncludes: other radiographs, mammography, myelography, mag-
netic resonance imaging, phlebography and echocardiography.
Table III Laboratory investigations
Total Mean per % oftotal cost
Investigations number patient oflaboratory costs
Haematology 828 16.6 28
Biochemistry 729 14.6 44
Microbiology 134 2.7 10
Histology/cytology 64 1.3 18
Total 100%
tions and bone radiographs a further 20%. Biochemical tests
accounted for 44% of the cost of laboratory investigations.
Costs
The cost of an overnight stay was calculated to be £129
(inclusive of overheads and capital charges). Those for visits
to the surgical, endocrine and chemotherapy clinics were £12,
£23 and £68 respectively. For the reasons given in the
Methods section, visits to radiotherapy clinics were arbit-
rarily set to be the same as for a visit to the endocrine
treatment clinic. The cost of each fraction of radiotherapy
was taken to be £37 (see Methods).
Overall costs of treatment for the 50 patients are shown in
Table IV, together with the proportion of costs attributable
to separate aspects of management. The mean cost per
patient was £7,620. The range of costs was wide (£317 to
£27,860). The most expensive management was that of a
patient who spent 133 days in hospital, attended clinics on 59
occasions, received 18 cycles of chemotherapy and three
courses of palliative radiotherapy (26 fractions) over a period
of 57 months.
Sensitivity analysis
Sensitivity analysis demonstrated that an increase of 2% in
the cost of in-patient stays (either because of higher prices or
because of increased use of resources) would increase the
total cost by 1%. The same overall change would be incurred
by an increase of 9% in out-patient clinic costs, by an
increase of 12% in cytotoxic drug costs, by an increase of
12% in the cost of radiological investigations or by a 30%
increase in laboratory investigation costs. A 60% change in
the cost of endocrine drugs would be required to change the
total cost by 1%.
Discussion
In this study an attempt has been made to calculate the total
usage of hospital resources and the overall cost of care for
patients with advanced breast cancer managed within a
specialised NHS unit. Resource usage was calculated by
abstracting detailed information from case records main-
tained specifically by the Breast Unit and Radiotherapy
Department. As has been noted by others (Hurley et al.,
1992), it is impossible to guarantee that these records were
complete. However, significant underrecording of resource
usage is considered unlikely.
Previous economic studies ofpatients with advanced breast
cancer have generally focussed either on the use of hospital
beds (Mattsson et al., 1979) or on the cost of out-patient
cytotoxic drug administration (Friedlander & Tattersall,
1982; Rees, 1985). Two studies, one from Australia, the other
from The Netherlands, have, however, recently been pub-
lished in which total resource usage has been calculated
(Hurley et al., 1992; de Koning et al., 1992). The data
presented by de Koning and coworkers for 68 patients with
advanced breast cancer who died between 1985 and 1989 can
Table IV Costs of treatment for all 50 patients
Mean cost
Total (f) perpatient %
In-patient stays 216,333 4,327 57
Out-patient clinics 43,714 874 12
Surgical treatment 9,000 180 2
Endocrine drugs 6,434 129 2
Chemotherapy drugs 31,964 639 8
Radiotherapy 28,305 566 7
Radiological investigations 32,155 643 9
Laboratory investigations 13,105 262 3
Total 381,010 7,620 100ADVANCED BREAST CANCER: USE OF RESOURCES 859
be directly compared with the findings in the current study
(Table V). Mean duration of stay in hospital was somewhat
longer in The Netherlands (45 days) than at Guy's (34 days).
In other respects, use of resources appears remarkably
similar.
Costing estimates involve assumptions and are always sub-
ject to error and possible criticism in studies of this type
(Hurley et al., 1992). In some countries, standard tariffs are
available and are used for costing studies (de Koning et al.,
1992). In the UK such information is not available (Rees,
1985). The approach adopted in the current study has
therefore been to calculate costs for individual components
of care wherever possible. Where this was not possible, as in
the case of radiotherapy costings, the best available published
data for the UK was used (Goddard et al., 1991). Because of
the likelihood of errors involved in the estimation of costs, a
sensitivity analysis was undertaken. Apart from the cost of
in-patient stays, moderate errors in the costs of separate
components of care make only small changes to the overall
costs.
The overall mean cost of hospital care calculated in this
study (£7,620) can be compared with results from other
countries. In the United States, the cost of treatment in the
last 6 months of life for breast cancer patients covered by the
Medicare programme was estimated to be $15,137 at 1984
prices (Baker et al., 1991). In the study from Australia
(Hurley et al., 1992), the median cost for 89 patients who had
died with metastatic breast cancer was Aus $11,948 (1988).
The authors noted that because of skewing of costs, mean
costs are higher than median costs. In that study hospital
visits comprised 54% of total costs and investigations 24%.
Costs in the current study can most closely be compared
with those reported from The Netherlands (de Koning et al.,
1992). Excluding the costs of Nursing home stays (which
were not assessed for our patients), de Koning et al. reported
a mean total cost of hospital care of US $15,850 (approx-
imately £8,450). Importantly, the proportions of total costs
attributable to different areas were very closely matched.
Thus, in-patient stays and clinic visits (including specialist
fees) accounted for 70% of total cost at Guy's and 71% in
The Netherlands. Diagnostic procedures accounted for 12%
and 11% of total costs respectively.
How does the estimated cost for caring for patients with
advanced breast cancer compare with the cost of treating
other conditions within the NHS? Lobo and coworkers
(1991) found that the cost of induction treatment for acute
myelogenous leukaemia was between £15,283 and £18,740. In
a study of surgical workload and cost, Ellis (1991) calculated
that the in-patient treatment costs (including surgery) for
transurethral prostatectomy and cholecystectomy were each
in the region of £1,200.
The largest component of the total cost of managing
advanced breast cancer is attributable to time spent as an
Table V Comparison of resource usage in two different studies
Guys Netherlands
(n = 50) (n = 68)
Mean survival
months
Median survival
months
Proportion of patients receiving:
Radiotherapy
Endocrine therapy
Chemotherapy
Mean duration of endocrine therapy
Mean duration of chemotherapy
Mean number of days in hospital
Mean number of diagnostic procedures:
X-rays
Isotope scans
CT scans
Pathology procedures
27 months 21.4
17 months 20.3
66% 59%
80% 84%
54% 69%
12 months 14 months
3.5 months 4 months
34 45
14.4 22
3.7 2
0.3 0.8
1.3 1.9
in-patient in hospital, staff salaries accounting for most of
this cost. The findings of this study demonstrate that most of
the time spent as an in-patient is due to complications arising
from the disease itself rather than to its treatment. Bone
metastasis, the commonest site of spread in patients with
breast cancer, can lead to prolonged hospitalisation, partic-
ularly when accompanied by spinal cord compression. Cere-
bral metastases, a less common site of spread, accounted for
a disproportionate amount of time in hospital.
As this study was conducted in the setting of a research
oriented tertiary referral unit, it was considered important to
estimate the extra time spent in hospital for clinical research.
Teaching hospitals receive supplementary funding to cover
some of the expenses associated with clinical research
through the Service Increment for Teaching and Research
(SIFTR). In the past, the extra costs associated with clinical
research have usually been poorly defined. In the future,
however, it is likely that both the NHS and the charitable
bodies funding clinical research will require much closer
scrutiny of the costs of such clinical research. In the current
study, the proportion of in-patient stays related to research
was 3%, 37 of the 42 days resulting from experimental
treatment given to one patient. Clearly, major differences in
the proportion of in-patient time attributable to research
could result from implementation of new clinical trials.
A widely held belief about cancer treatment is that it is
expensive because of the high cost of cytotoxic drugs.
Cytotoxic agents are certainly more expensive than many
other drugs and the costs are easy to identify, but as can be
seen from this study, they account for a relatively small
proportion (8%) of the total cost of patient management.
Palliative radiotherapy accounted for a similar proportion of
the total cost (7%). The cost of cytotoxic drugs combined
with the cost of running the chemotherapy clinic and the cost
of time spent in hospital related to chemotherapy accounted
for 16% of the total cost. In this study, it was not possible to
assess the relative benefits of the different treatments. It is to
be hoped that such assessments will become possible when
the results of prospective audit studies are available (Rubens,
1991).
What are the practical implications of a study such as this?
Clearly any measures that can reduce time spent in hospital
are likely to result in major savings but only if the beds are
closed or are put to alternative use. In this unit, investiga-
tions are carried out on an out-patient basis whenever pos-
sible although for some patients who are unwell and have
long distances to travel this is impractical. Similarly,
radiotherapy is given as an out-patient whenever possible,
but for patients who are sick or immobile, this is not feasible
or humane. No account was taken in this study of the costs
of patient transport. One way in which in-patient stays can
potentially be reduced is by adopting shorter schedules of
radiotherapy, involving fewer fractions of treatment. The
equivalence of the benefit in terms of palliation of shorter
courses of radiotherapy is now becoming apparent (Borgelt
et al., 1980; Gelber et al., 1981), and has led to changes in
treatment policy within the unit. It should be noted that the
patients in this study first developed advanced breast cancer
between 1978 and 1990.
Prevention and early detection of the complications of
bone metastases would have a major impact on the overall
cost of treatment. Studies are currently in progress to assess
the role of bisphosphonates in this regard. If patients who
are at high risk of developing bone metastases can be
identified and if these agents can reduce the incidence of
pathological fractures, this could lead both to improvement
in quality of life for breast cancer patients and to con-
siderable savings for the NHS. Early detection of spinal cord
compression should also be a priority area for clinical
research. If patients could be identified early, perhaps by the
use of magnetic resonance imaging, the costs of an expensive
investigation might of offset by a reduction in the time spent
in hospital.
Finally, close collaboration with hospices and home care
support teams can also help to reduce costs and, we believe,860 M.A. RICHARDS et al.
significantly improve quality of life for patients and their
relatives. The benefit to the patients and to the NHS of such
services, many of which are funded from charitable sources,
is considerable.
We are grateful to Professor M.N. Maisey and Mr N. Bosanquet for
providing information on the costs of radiological procedures and to
Professor D.A. Levison and Mr P. Wozencroft for information on
laboratory costs. Ms C. Ashley and Mr R. White, from the Finance
Department at Guy's Hospital, kindly provided information relating
to the cost of indirect overheads and capital charges.
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